> Genzyme will file a new application for Lumizyme for Pompe disease by the middle of May. Report
> The UK's Antisoma says it will sell its leukemia drug fludarabine in the next two months, providing enough capital to last through mid-2011. Story
> Isolagen announced that it has entered into secured promissory notes and security agreements with eight lenders in which the company borrowed $500,417.00 in principal. The notes bear interest at a rate of 20% per annum with principal and interest on the notes due on the earlier of June 20, 2009 or the date that the company files for voluntary or involuntary bankruptcy. Isolagen release
> The FDA has granted priority review status to Wyeth Pharmaceuticals' BLA for Prevnar 13, Pneumococcal 13-valent Conjugate Vaccine. Wyeth release
> The nonprofit Aeras Global TB Vaccine Foundation in Rockville, MD has opened the doors to a new manufacturing facility that has the capacity to satisfy the worldwide demand for TB vaccine. Report
> A cardiology society is raising the red flag on drug-mixing: The clot-busting Plavix and heartburn meds like Nexium shouldn't be taken together. Report
> Andrew Witty puts charity to work again. The GlaxoSmithKline CEO, who's already pledged to slash prices for drugs sold in poor countries, now is offering a 50 percent discount on meds for U.S. patients who are uninsured. Report
> The U.K.'s cost watchdogs strike again. The National Institute for Health and Clinical Excellence gave Bayer's cancer drug Nexavar the heave-ho, saying it shouldn't be given to National Health Service patients with liver cancer. Though the decision isn't final--it's open to negotiation--it's a setback for Bayer and its developer-partner Onyx Pharmaceuticals. Nexavar report
And Finally... Knome says that it has a winning bidder for its eBay offering of a full genome sequencing. An unknown person won the auction-used to raise money for the Archon X Prize for genomic sequencing-for the minimum bid of $68,000. Story